Archives of Virology

, Volume 164, Issue 3, pp 775–786 | Cite as

Adenovirus 5 produces obesity and adverse metabolic, morphological, and functional changes in the long term in animals fed a balanced diet or a high-fat diet: a study on hamsters

  • Daniel A. Montes-Galindo
  • Ana C. Espiritu-Mojarro
  • Valery Melnikov
  • Norma A. Moy-López
  • Alejandro D. Soriano-Hernandez
  • Hector R. Galvan-Salazar
  • Jorge Guzman-Muñiz
  • Jose Guzman-Esquivel
  • Margarita L. Martinez-Fierro
  • Iram P. Rodriguez-Sanchez
  • Brenda Paz-Michel
  • Sergio A. Zaizar-Fregoso
  • Carmen A. Sanchez-Ramirez
  • Mario Ramirez-Flores
  • Ivan Delgado-EncisoEmail author
Original Article


Adenovirus 5 (Ad-5) infection is a common cause of acute respiratory infections and the main vector used in gene therapy. There are few studies on the relationship of Ad-5 to obesity. In the present study, we evaluated the chronic effects of Ad-5 infection on golden (Syrian) hamsters fed either a balanced diet (BD) or a high-fat diet (HFD). After a single inoculation with Ad-5 (1 × 107 pfu), the body weight of the animals was measured weekly. Medium-term (22 weeks) serum biochemical analyses and long-term (44 weeks) liver morphology, adiposity, and locomotive functionality (movement velocity) assessments were carried out. In the animals fed the BD, adenovirus infection produced hyperglycemia and hyperlipidemia. In the long term, it produced a 57% increase in epididymal pad fat and a 30% body weight gain compared with uninoculated animals. In addition, morphological changes related to non-alcoholic fatty liver disease (NAFLD) were observed. The animals fed the HFD had similar but more severe changes. In addition, the hamsters presented an obesity paradox: at the end of the study, the animals that had the most morphological and functional changes (significantly reduced movement velocity) had the lowest body weight. Despite the fact that an HFD appears to be a more harmful factor in the long term than adenovirus infection alone, infection could increase the severity of harmful effects in individuals with an HFD. Epidemiological studies are needed to evaluate the effect of adenovirus as a precursor of chronic liver and cardiovascular diseases, including the chronic effects of gene therapy.



The present study was completed using equipment resources obtained through Grant no. 270485 from the 2016-INFRAESTRUCTURA-CONACYT (author ADSH) and Grant no. 272792 from the 2016-FOSISS-CONACYT (author IDE).

Compliance with ethical standards

Disclosure of potential conflicts of interest

Esteripharma Mexico SA de CV provided support in the form of salaries for author BPM but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. That commercial affiliation does not alter our adherence to the “Archives of Virology” policies on sharing data and materials. The others authors declare that they have no conflict of interest.

Ethical approval

The trials complied with the national and international legal and ethical requirements applicable to pre-clinical research. The experimental protocols were approved by the Research Ethics Committee of the School of Medicine of the University of Colima, Mexico (Protocol Number: 14-016). The animals were handled according to institutional guidelines, the Mexican official norm regulating laboratory animal use (NOM-062-ZOO-1999), and the guide for the care and use of laboratory animals issued by the National Academy of Sciences of the United States of America (2011). All animals were euthanized according to the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals: 2013 Edition.

Consent for publication

All authors consent to publication.

Supplementary material

705_2018_4132_MOESM1_ESM.xlsx (25 kb)
Supplementary material 1 (XLSX 24 kb)
705_2018_4132_MOESM2_ESM.docx (28 kb)
Supplementary material 2 (DOCX 28 kb)


  1. 1.
    Atkinson RL (2007) Viruses as an etiology of obesity. Mayo Clin Proc 82:1192–1198CrossRefGoogle Scholar
  2. 2.
    Atkinson RL (2008) Could viruses contribute to the worldwide epidemic of obesity? Int J Pediatr Obes 3:37–43. CrossRefGoogle Scholar
  3. 3.
    Pasarica M, Mashtalir N, McAllister EJ et al (2008) Adipogenic human adenovirus Ad-36 induces commitment, differentiation, and lipid accumulation in human adipose-derived stem cells. Stem Cells 26:969–978. CrossRefGoogle Scholar
  4. 4.
    Voss JD, Atkinson RL, Dhurandhar NV (2015) Role of adenoviruses in obesity. Rev Med Virol. Google Scholar
  5. 5.
    Na HN, Hegde V, Dubuisson O, Dhurandhar NV (2016) E4orf1 enhances glucose uptake independent of proximal insulin signaling. PLoS One 11:e0161275. CrossRefGoogle Scholar
  6. 6.
    Rogers PM, Fusinski KA, Rathod MA et al (2008) Human adenovirus Ad-36 induces adipogenesis via its E4 orf-1 gene. Int J Obes 32:397–406. CrossRefGoogle Scholar
  7. 7.
    So PW, Herlihy AH, Bell JD (2005) Adiposity induced by adenovirus 5 inoculation. Int J Obes 29:603–606. CrossRefGoogle Scholar
  8. 8.
    Cakmakliogullari EK, Sanlidag T, Ersoy B et al (2014) Are human adenovirus-5 and 36 associated with obesity in children? J Investig Med 62:821–824 (10.231/JIM.0000000000000084) CrossRefGoogle Scholar
  9. 9.
    Rhee EG, Barouch DH (2015) 145—Adenoviruses. In: Bennett JE, Dolin R, Blaser MJ (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 8th edn. Content Repository Only!, Philadelphia, pp 1787–1793.e2Google Scholar
  10. 10.
    Schulick AH, Vassalli G, Dunn PF et al (1997) Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. Google Scholar
  11. 11.
    Goossens PH, Vogels R, Pieterman E et al (2001) The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis Rheum.;2-D Google Scholar
  12. 12.
    Sun C, Zhang Y, Feng L et al (2011) Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 29:3837–3841. CrossRefGoogle Scholar
  13. 13.
    Zhang S, Huang W, Zhou X et al (2013) Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol. Google Scholar
  14. 14.
    Nwanegbo E, Vardas E, Gao W et al (2004) Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Vaccine Immunol. Google Scholar
  15. 15.
    Bortolanza S, Alzuguren P, Buñuales M et al (2007) Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 18:681–690. CrossRefGoogle Scholar
  16. 16.
    Thomas MA, Spencer JF, La Regina MC et al (2006) Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 66:1270–1276. CrossRefGoogle Scholar
  17. 17.
    Thomas MA, Spencer JF, Toth K et al (2008) Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian Hamster model. Mol Ther 16:1665–1673. CrossRefGoogle Scholar
  18. 18.
    Tollefson AE, Ying B, Spencer JF et al (2017) Pathology in permissive syrian hamsters after infection with species C human adenovirus (HAdV-C) is the result of virus replication: HAdV-C6 replicates more and causes more pathology than HAdV-C5. J Virol. Google Scholar
  19. 19.
    Gu SH, Kim YS, Baek LJ et al (2015) Lethal disease in infant and juvenile Syrian hamsters experimentally infected with Imjin virus, a newfound crocidurine shrew-borne hantavirus. Infect Genet Evol 36:231–239. CrossRefGoogle Scholar
  20. 20.
    Baseler L, de Wit E, Scott DP et al (2015) Syrian Hamsters (Mesocricetus auratus) oronasally inoculated with a nipah virus isolate from bangladesh or malaysia develop similar respiratory tract lesions. Vet Pathol 52:38–45. CrossRefGoogle Scholar
  21. 21.
    Dillard A, Matthan NR, Spartano NL et al (2013) Background diet and fat type alters plasma lipoprotein response but not aortic cholesterol accumulation in F1B Golden Syrian hamsters. Lipids 48:1177–1184. CrossRefGoogle Scholar
  22. 22.
    Dorfman SE, Wang S, Vega-López S et al (2005) Dietary fatty acids and cholesterol differentially modulate HDL cholesterol metabolism in Golden-Syrian hamsters. J Nutr 135:492–498CrossRefGoogle Scholar
  23. 23.
    Delgado-Enciso I, Galván-Salazar HR, Coronel-Tene CG et al (2008) Preclinical evaluation of the therapeutic effect of adenoviral vectors in Human papillomavirus-dependent neoplasias. Rev Investig Clin 60:101–106Google Scholar
  24. 24.
    Fernandes MR, de Lima NV, Rezende KS et al (2016) Animal models of obesity in rodents. An integrative review. Acta Cir Bras. Google Scholar
  25. 25.
    Trefna M, Goris M, Thissen CMC et al (2017) The influence of sex and diet on the characteristics of hibernation in Syrian hamsters. J Comp Physiol B Biochem Syst Environ Physiol. Google Scholar
  26. 26.
    Spady DK, Dietschy JM (1988) Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster. J Clin Invest. Google Scholar
  27. 27.
    Spady DK, Dietschy JM (1989) Interaction of aging and dietary fat in the regulation of low density lipoprotein transport in the hamster. J Lipid Res 30:559–569Google Scholar
  28. 28.
    Development O Organisation for EC (2000) Guidance document on the recognition, assessment, and use of clinical signs as humane endpoints for experimental animals used in safety evaluation (ENV/JM/MONO 7)Google Scholar
  29. 29.
    Arencibia-Arrebola DF, Rosario-Fernández LA, López-Feria Y et al (2003) Algunas consideraciones sobre la determinación de la toxicidad aguda. Rev Toxicol en Línea. Google Scholar
  30. 30.
    Delgado-Enciso I, Martinez-Garza SG, Rojas-Martinez A et al (2001) 677T mutation of the MTHFR gene in adenomas and colorectal cancer in a population sample from the Northeastern Mexico. Preliminary results. Rev Gastroenterol Mex 66:32–37Google Scholar
  31. 31.
    Delgado-Enciso I, Cervantes-García D, Martínez-Dávila IA et al (2007) A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms. J Gene Med 9:85–861. CrossRefGoogle Scholar
  32. 32.
    Pasarica M, Loiler S, Dhurandhar NV (2008) Acute effect of infection by adipogenic human adenovirus Ad36. Arch Virol 153:2097–2102. CrossRefGoogle Scholar
  33. 33.
    Birt DF, Patil K, Pour PM (1985) Comparative studies on the effects of semipurified and commercial diet on longevity and spontaneous and induced lesions in the Syrian Golden Hamster. Nutr Cancer 7:167–177. CrossRefGoogle Scholar
  34. 34.
    Stoll S, Hafner U, Kränzlin B, Müller WE (1997) Chronic treatment of syrian hamsters with low-dose selegiline increases life span in females but not males. Neurobiol Aging 18:205–211. CrossRefGoogle Scholar
  35. 35.
    Zacour ME, Gardiner PF (1986) Long-term mild endurance exercise effects on the age-associated evolution of hindlimb muscle characteristics in hamsters. Mech Ageing Dev 37:13–26. CrossRefGoogle Scholar
  36. 36.
    Davis FC, Viswanathan N (1998) Stability of circadian timing with age in Syrian hamsters. Am J Physiol 275:R960–R968Google Scholar
  37. 37.
    Wehner AP, Olson RJ, Busch RH (1976) In creased life span and decreased weight in hamsters exposed to cigarette smoke. Arch Environ Health 31:146–153. CrossRefGoogle Scholar
  38. 38.
    Tatem KS, Quinn JL, Phadke A et al (2014) Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. J Vis Exp. Google Scholar
  39. 39.
    Turner KM, Burne THJ (2014) Comprehensive behavioural analysis of long Evans and Sprague-Dawley rats reveals differential effects of housing conditions on tests relevant to neuropsychiatric disorders. PLoS One. Google Scholar
  40. 40.
    Kabuki Y, Yamane H, Hamasu K, Furuse M (2008) Different locomotor activities and monoamine levels in the brains of Djungarian hamsters (D. sungorus) and Roborovskii hamsters (D. roborovskii). Exp Anim. 5:10. Google Scholar
  41. 41.
    Kanda LL, Louon L, Straley K (2012) Stability in activity and boldness across time and context in captive Siberian dwarf hamsters. Ethology. Google Scholar
  42. 42.
    Kabuki Y, Shigemi K, Hamasu K, Furuse M (2009) l-DOPA attenuates hyperactivity of Roborovskii hamsters. Behav Pharmacol. Google Scholar
  43. 43.
    Stanford SC (2007) The open field test: reinventing the wheel. J Psychopharmacol 21:134–135. CrossRefGoogle Scholar
  44. 44.
    Estrada-Reyes R, López-Rubalcava C, Ferreyra-Cruz OA et al (2014) Central nervous system effects and chemical composition of two subspecies of Agastache mexicana; an ethnomedicine of Mexico. J Ethnopharmacol 153:98–110. CrossRefGoogle Scholar
  45. 45.
    Delgado-Enciso I, Garciá-Rivera A, Madrigal-Pérez MVM et al (2014) Protective effect of doxycycline on germinal epithelial loss caused by a high-fat diet. Int Urol Nephrol 46:895–899. CrossRefGoogle Scholar
  46. 46.
    Delgado-Enciso I, Paz-Garcia J, Rodriguez-Hernandez A, Madrigal-Perez VM, Cabrera-Licona A, Garcia-Rivera A, Soriano-Hernandez AD, Cortes-Bazan JL, Galvan-Salazar HR, Valtierra-Alvarez J, Guzman-Esquivel J (2017) A promising novel formulation for articular cartilage regeneration: preclinical evaluation of a treatment that produces SOX9 overexpression in human synovial fluid cells. Mol Med Rep. Google Scholar
  47. 47.
    Madrigal-Perez VM, García-Rivera A, Rodriguez-Hernandez A et al (2015) Preclinical analysis of nonsteroidal anti-inflammatory drug usefulness for the simultaneous prevention of steatohepatitis, atherosclerosis and hyperlipidemia. Int J Clin Exp Med 8:22477Google Scholar
  48. 48.
    Garcìa-Rivera A, Madrigal-Perez VM, Rodriguez-Hernandez A et al (2014) A simple and low-cost experimental mouse model for the simultaneous study of steatohepatitis and preclinical atherosclerosis. Asian J Anim Vet Adv 9:202–210. CrossRefGoogle Scholar
  49. 49.
    Rosen ED, Spiegelman BM (2014) What we talk about when we talk about fat. Cell 156:20–44CrossRefGoogle Scholar
  50. 50.
    Rodríguez E, Ribot J, Rodríguez AM, Palou A (2004) PPAR-gamma2 expression in response to cafeteria diet: gender- and depot-specific effects. Obes Res 12:1455–1463. CrossRefGoogle Scholar
  51. 51.
    Grizzi F, Chiriva-Internati M (2007) Human binucleate hepatocytes: are they a defence during chronic liver diseases? Med Hypotheses 69:258–261. CrossRefGoogle Scholar
  52. 52.
    Gentric G, Desdouets C, Celton-Morizur S (2012) Hepatocytes polyploidization and cell cycle control in liver physiopathology. Int J Hepatol 2012:1–8. CrossRefGoogle Scholar
  53. 53.
    Gentric G, Maillet V, Paradis V et al (2015) Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. J Clin Invest 125:981–992. CrossRefGoogle Scholar
  54. 54.
    Yang SQ, Lin HZ, Hwang J et al (2001) Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 61:5016–5023Google Scholar
  55. 55.
    Jarrar BM, Taib NT (2012) Histological and histochemical alterations in the liver induced by lead chronic toxicity. Saudi J Biol Sci 19:203–210. CrossRefGoogle Scholar
  56. 56.
    Han TS, Lean ME (2016) A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis 5:2048004016633371. Google Scholar
  57. 57.
    Murillo-Zamora E, García-Ceballos R, Delgado-Enciso I et al (2016) Regional-level estimation of expected years of life lost attributable to overweight and obesity among Mexican adults. Glob Health Action 9:31642. CrossRefGoogle Scholar
  58. 58.
    Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-Alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153. CrossRefGoogle Scholar
  59. 59.
    Fotbolcu H, Zorlu E (2016) Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol 22:4079–4090CrossRefGoogle Scholar
  60. 60.
    Enomoto H, Bando Y, Nakamura H et al (2015) Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol 21:7427–7435. CrossRefGoogle Scholar
  61. 61.
    Miyashita Y, Nishimura R, Morimoto A et al (2007) Glycated albumin is low in obese, type 2 diabetic patients. Diabetes Res Clin Pract 78:51–55. CrossRefGoogle Scholar
  62. 62.
    Koga M, Matsumoto S, Saito H, Kasayama S (2006) Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 53:387–391. CrossRefGoogle Scholar
  63. 63.
    van den Berg EH, Amini M, Schreuder TCMA et al (2017) Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: a large Dutch population cohort. PLoS One 12:e0171502. CrossRefGoogle Scholar
  64. 64.
    Devi DV, Latha MM, Sumapreethi A, Sharma SSB, Priyanka K (2013) A study of non alcoholic fatty liver disease in patients with metabolic syndrome. J Evol Med Dent Sci 2:375–383. CrossRefGoogle Scholar
  65. 65.
    Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC (2008) Albumin levels predict survival in patients with systolic heart failure. Am Heart J 155:883–889. CrossRefGoogle Scholar
  66. 66.
    Nelson CL, Elkassabany NM, Kamath AF, Liu J (2015) Low albumin levels, more than morbid obesity, are associated with complications after TKA. Clin Orthop Relat Res 473:3163–3172. CrossRefGoogle Scholar
  67. 67.
    Kang HG, Dingwell JB (2008) Effects of walking speed, strength and range of motion on gait stability in healthy older adults. J Biomech 41:2899–2905. CrossRefGoogle Scholar
  68. 68.
    Wu JP, Hsieh CH, Ho TJ et al (2014) Secondhand smoke exposure toxicity accelerates age-related cardiac disease in old hamsters. BMC Cardiovasc Disord 14:195. CrossRefGoogle Scholar
  69. 69.
    De Schutter A, Lavie CJ, Milani RV (2014) The impact of obesity on risk factors and prevalence and prognosis of coronary heart disease-the obesity paradox. Prog Cardiovasc Dis 56:401–408. CrossRefGoogle Scholar
  70. 70.
    Feare CJ (2002) Influence of date and body mass at fledging on long-term survival of sooty terns sterna fuscata. Mar Ornithol 30:46–47Google Scholar
  71. 71.
    Spelta F, Fratta Pasini AM, Cazzoletti L, Ferrari M (2018) Body weight and mortality in COPD: focus on the obesity paradox. Eat Weight Disord 23:15–22CrossRefGoogle Scholar
  72. 72.
    Amundson DE, Djurkovic S, Matwiyoff GN (2010) The obesity paradox. Crit Care Clin 26:583–596CrossRefGoogle Scholar
  73. 73.
    Esser N, Legrand-Poels S, Piette J et al (2014) Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105:141–150CrossRefGoogle Scholar
  74. 74.
    Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454. CrossRefGoogle Scholar
  75. 75.
    Wang H, Xu H, Qu L et al (2016) Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients. Eur J Gastroenterol Hepatol 28:997–1002. CrossRefGoogle Scholar
  76. 76.
    Hasan HR, Aburahma NNA, Al-Kazaz AKA (2017) Proteins level in sera and saliva of type 2 diabetic iraqi patients with and without proliferative retinopathy. Orient J Chem 33:2776–2786. CrossRefGoogle Scholar
  77. 77.
    He J, Pan H, Liang W et al (2017) Prognostic effect of albumin-to-globulin ratio in patients with solid tumors: a systematic review and meta-analysis. J Cancer 8:4002–4010. CrossRefGoogle Scholar
  78. 78.
    Bazick J, Donithan M, Neuschwander-Tetri BA et al (2015) Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care 38:1347–1355. CrossRefGoogle Scholar
  79. 79.
    Hassan HR, Abdul Sattar A (2015) Influence of diabetes disease on concentration of total protein, albumin and globulins in saliva and serum: a comparative study. Iraqi Natl Chem 15:1–11Google Scholar
  80. 80.
    Malawadi B, Adiga U (2016) Plasma proteins in type 2 diabetes mellitus. IOSR J Biotechnol Biochem 2:2455–2464Google Scholar
  81. 81.
    Garnett CT, Erdman D, Xu W, Gooding LR (2002) Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 76:10608–10616. CrossRefGoogle Scholar
  82. 82.
    Huo L, Lyons J, Magliano DJ (2016) Infectious and environmental influences on the obesity epidemic. Curr Obes Rep 5:375–382CrossRefGoogle Scholar
  83. 83.
    Pasarica M, Shin AC, Yu M et al (2006) Human adenovirus 36 induces adiposity, increases insulin sensitivity, and alters hypothalamic monoamines in rats. Obesity 14:1905–1913. CrossRefGoogle Scholar
  84. 84.
    Bouwman JJM, Visseren FLJ, Bouter KP, Diepersloot RJA (2008) Infection-induced inflammatory response of adipocytes in vitro. Int J Obes 32:892–901. CrossRefGoogle Scholar
  85. 85.
    Sato N, Kobayashi K, Inoguchi T et al (2005) Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology 146:273–279. CrossRefGoogle Scholar
  86. 86.
    Na HN, Kim J, Lee HS et al (2012) Association of human adenovirus-36 in overweight Korean adults. Int J Obes 36:281–285. CrossRefGoogle Scholar
  87. 87.
    Na H-N, Kim H, Nam J-H (2014) Prophylactic and therapeutic vaccines for obesity. Clin Exp Vaccine Res 3:37–41. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Daniel A. Montes-Galindo
    • 1
    • 2
  • Ana C. Espiritu-Mojarro
    • 2
    • 3
  • Valery Melnikov
    • 1
  • Norma A. Moy-López
    • 4
  • Alejandro D. Soriano-Hernandez
    • 1
    • 2
  • Hector R. Galvan-Salazar
    • 2
    • 3
  • Jorge Guzman-Muñiz
    • 4
  • Jose Guzman-Esquivel
    • 3
  • Margarita L. Martinez-Fierro
    • 5
  • Iram P. Rodriguez-Sanchez
    • 6
  • Brenda Paz-Michel
    • 7
  • Sergio A. Zaizar-Fregoso
    • 1
    • 2
  • Carmen A. Sanchez-Ramirez
    • 1
  • Mario Ramirez-Flores
    • 1
  • Ivan Delgado-Enciso
    • 1
    • 2
    Email author
  1. 1.Department of Molecular Medicine, School of MedicineUniversity of ColimaColimaMexico
  2. 2.Department of ResearchCancerology State Institute,Colima State Health ServicesColimaMexico
  3. 3.Department of ResearchMexican Social Security InstituteColimaMexico
  4. 4.Laboratory of Neuroscience, School of PsychologyUniversity of ColimaColimaMexico
  5. 5.Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health SciencesZacatecas Autonomous UniversityZacatecasMexico
  6. 6.Molecular and Structural Physiology Laboratory, School of Biological SciencesUniversidad Autónoma de Nuevo LeónMonterreyMexico
  7. 7.Esteripharma MexicoMexico CityMexico

Personalised recommendations